An Initial Study of AZD7325 in Adults With Fragile X Syndrome
Status:
Completed
Trial end date:
2020-06-18
Target enrollment:
Participant gender:
Summary
This study will investigate the safety, tolerability and blood pharmacodynamics of treatment
with oral administration of AZD7325 at 5 mg BID, 15 mg BID, and placebo BID, in adults with
Fragile X Syndrome. The study also will also investigate measures of efficacy and biomarkers
during treatment.